Welcome to our dedicated page for DBV Technologies S.A. news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies S.A. stock.
DBV Technologies S.A. (symbol: DBVT) is a clinical-stage specialty biopharmaceutical company revolutionizing the treatment of food allergies, a significant and growing public health issue. Founded in 2002, the company has developed a groundbreaking technology platform known as Viaskin®.
Viaskin® employs epicutaneous immunotherapy (EPIT), a proprietary method that administers allergens through an epicutaneous patch applied to intact skin. This innovative approach targets Langerhans cells, specialized immune cells in the skin, which capture the allergen and migrate to the lymph nodes. This mechanism allows for activation of the immune system without introducing the allergen into the bloodstream, thus minimizing systemic exposure and the risk of severe allergic reactions.
DBV Technologies' flagship product, Viaskin Peanut, is designed for peanut-allergic patients. The patch aims to improve patient tolerability to peanuts and significantly reduce the risk of life-threatening allergic reactions upon accidental exposure. Clinical trials have demonstrated the product's efficacy and safety, making it a promising solution for millions of individuals affected by peanut allergies.
In addition to peanut allergies, DBV Technologies is expanding its portfolio to address other food allergies like milk. The company's robust pipeline and innovative approach position it at the forefront of allergy treatment research.
DBV Technologies has secured multiple worldwide patents for its Viaskin® technology, underlining its pioneering role in the field of immunotherapy. The company continually collaborates with leading research institutions and partners to advance its clinical programs and bring new therapies to market.
Recent achievements include significant milestones in clinical trials, regulatory submissions, and strategic partnerships, reflecting DBV Technologies' commitment to developing safe and effective treatments for food allergies. The company's dedication to addressing unmet medical needs ensures it remains a crucial player in the biopharmaceutical landscape.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for Monday, September 9, 2024, in New York City. Daniel Tassé, the company's Chief Executive Officer, will engage in a fireside chat at 3:00 pm ET.
Investors and interested parties can access a live webcast of the presentation through a provided link or via the Events section of DBV Technologies' Investors website. For those unable to attend live, a replay will be available on the company's website for 90 days following the event, offering extended access to the presentation content.
DBV Technologies (DBVT) has released an update on its total number of voting rights and shares as of July 31, 2024. The company reported a total of 96,498,927 shares outstanding. The total gross voting rights also stand at 96,498,927, while the total net voting rights are 96,214,457. This information is provided in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. DBV Technologies is listed on the NYSE Euronext Paris under the ISIN Code FR 0010417345.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), a clinical-stage biopharmaceutical company focused on food allergies and immunologic conditions, has announced the filing of its 2024 Half-Year Report for the semester ended June 30, 2024. The report has been filed with the French market authority, Autorité des Marchés Financiers (AMF).
The 2024 Half-Year Report is now available for consultation or download in French on the company's website (www.dbv-technologies.com) under the Investors/Financial Information section, as well as on the AMF website (www.amf-france.org). Interested parties can also request a free copy by mail or email from DBV Technologies.
DBV Technologies (DBVT) provided updates on its Viaskin Peanut program and reported Q2 2024 financial results. Key highlights:
- VITESSE Phase 3 study enrollment for 4-7 year olds with peanut allergy is on track to complete by Q3 2024
- Submitted labeling proposal to FDA for COMFORT Toddlers study in 1-3 year olds
- Q2 2024 cash balance of $66.2 million, with runway extended into Q1 2025 due to cost-saving measures
- Q2 2024 net loss of $60.5 million or $0.63 per share
- Operating expenses increased to $65.0 million in H1 2024 vs $50.7 million in H1 2023, driven by R&D costs
The company faces substantial doubt about its ability to continue as a going concern beyond Q1 2025 without additional capital.
DBV Technologies (Nasdaq: DBVT), a clinical-stage biopharmaceutical company, has announced it will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to discuss its second quarter 2024 financial results and provide a business update. Interested participants can join the call via teleconference or access the live webcast on the company's website. The event details are as follows:
- Teleconference numbers:
United States: +1-877-346-6112
International: +1-848-280-6350
- Webcast: Available on the Investors & Media section of DBV's website
A replay of the presentation will be accessible on the company's website after the event.
DBV Technologies, a clinical-stage biopharmaceutical company listed on Euronext and Nasdaq under the ticker DBVT, released its half-year report on the liquidity contract with ODDO BHF. As of June 30, 2024, the liquidity account held 303,744 DBV Technologies shares and €62,415.60. This is an increase from the initial assets on July 1, 2018, which included 41,159 shares and €432,367.25. Between January 1, 2024, and June 30, 2024, 912 buy transactions and 694 sales transactions were conducted. The total volumes traded were 299,986 shares and €397,966 for purchases, and 219,230 shares and €310,114 for sales.
DBV Technologies, a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Daniel Tassé will engage in a fireside chat on June 10, 2024, at 8:00 am EDT, and attend one-on-one investor meetings. The company focuses on treating food allergies and other immunologic conditions with significant unmet needs. A live webcast and a 90-day replay of the presentation will be available on DBV Technologies’ Investor Relations website.
As of May 31, 2024, the company reported a total of 96,493,078 shares outstanding. The total number of voting rights is 96,493,078, with a net voting right count of 96,236,383. These figures are in accordance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies announced a change in the ADS ratio from one ADS for one-half of an ordinary share to one ADS for one ordinary share, effective June 7, 2024. This change will act as a one-for-two reverse ADS split, aiming to regain compliance with Nasdaq's minimum bid price requirement. Registered ADS holders must surrender their certificated ADSs for cancellation and will receive new ADSs in exchange. Uncertificated ADSs will be automatically exchanged. No fractional new ADSs will be issued; instead, they will be aggregated and sold, with proceeds distributed to ADS holders. This change will not affect DBV's underlying ordinary shares.
DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress from May 31 to June 3, 2024, in Valencia, Spain. The company will present data on accidental peanut consumption from its EPITOPE Phase 3 study and its ongoing open-label extension study in peanut-allergic toddlers aged 1 to 3 years.
The presentation by Dr. Nicolette Arends will describe the data collection. DBV will also host a symposium moderated by Dr. Stefania Arasi and Dr. Philippe Eigenmann, featuring lectures on the potential clinical applications of epicutaneous immunotherapy. Additionally, DBV will have an exhibit booth to showcase their ongoing clinical trials in peanut-allergic children.
CEO Daniel Tassé emphasized the importance of long-term safety and clinical data, while Chief Medical Officer Pharis Mohideen highlighted the real-world benefits of Viaskin Peanut in reducing allergic reactions over time.
FAQ
What is the current stock price of DBV Technologies S.A. (DBVT)?
What is the market cap of DBV Technologies S.A. (DBVT)?
What does DBV Technologies S.A. specialize in?
What is Viaskin® technology?
What is Viaskin Peanut?
How does Viaskin® technology minimize the risk of allergic reactions?
What other food allergies is DBV Technologies targeting?
When was DBV Technologies founded?
What are some recent achievements of DBV Technologies?
What is the significance of DBV Technologies' patents?
How does DBV Technologies collaborate with other institutions?
What is the financial condition of DBV Technologies?
